Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



ASCO: Bristol-Myers Squibb and Merck Don't Disappoint

We knew going into American Society of Clinical Oncology annual meeting that immuno-oncology would be a big focus. And Bristol-Myers Squibb (NYSE: BMY  ) and Merck (NYSE: MRK  ) didn't disappoint.

Rather than attacking the tumor directly, immuno-oncology drugs encourage the patient's immune system to attack the cancer. Bristol-Myers Squibb already has Yervoy on the market, a drug that activates the immune system. And both Bristol-Myers Squibb and Merck are developing a second class of immuno-oncology drug, called PD1 inhibitors, that inhibit a signal that tumor cells use to tell the immune system to not attack them. Inhibiting the inhibitor results in activation of the immune system.

The PD1 drugs have already put up remarkable data in patients with melanoma, but at ASCO, Bristol-Myers Squibb and Merck showed the class's true potential, expanding their use into other types of cancer. Merck's MK-3475 worked well in head and neck cancer, producing a 45% response rate in patients that over-express the target protein. And Bristol-Myers Squibb showed that nivolumab worked well in kidney cancer in combination with Yervoy, with the response rate about double what the monotherapy produced.

Watch the following video for more insight into the oncology confab from senior biotech specialist Brian Orelli and health-care analyst David Williamson.

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2982678, ~/Articles/ArticleHandler.aspx, 9/4/2015 7:32:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:00 PM
BMY $57.30 Down -1.45 -2.47%
Bristol-Myers Squi… CAPS Rating: ****
MRK $51.59 Down -1.06 -2.01%
Merck & Co., Inc. CAPS Rating: ****